Other
Adrenomyeloneuropathy
5
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Adrenomyeloneuropathy is an early-stage landscape with 5 programs across 4 companies. The most active players are Takeda, MedDay Pharmaceuticals SA, Biogen. 1 therapy is approved with 3 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 21
Analysis
Trial Status
4
clinical trials
Completed2 · 50%
Recruiting1 · 25%
Terminated1 · 25%
Clinical Trials
Trial Activity
Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy
Completed·—·Phase 2·NCT03864523·18 enrolled
Dimethyl Fumarate in Adrenomyeloneuropathy
Recruiting·—·Phase 2/3·NCT06513533·40 enrolled
A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy
Terminated·Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT00545597·240 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)